Invest in Arcade Therapeutics

We are excited to launch this Equity Crowdfunding Round, offering the opportunity to become owners in Arcade alongside our institutional investors.

Today, we are failing to reach many people in need of help.  70% of primary care visits are related to mental health conditions, and doctors don't have enough options to get patients early help. This leads to a large percentage of patients not seeking care, along with a large undiagnosed population left struggling with their mental health.

Sources: HHS, CDC, NIH, Project Hope

190M Americans play video games today, according to the Entertainment Software Association.

Mobile games are most popular with adults, and allow for access anytime, anywhere and are used by all cultural backgrounds.



Our first game, StarStarter for Anxiety, is now available, as a science-backed cognitive training game to help manage the symptoms of anxiety. We have begun launches with universities, behavioral health providers, and primary care providers. It's available as a first-line treatment or complementary to other treatments, as a non-prescription option.

And it works! Our most recent clinical trial delivered excellent results within a 30 days, showing similar effectiveness to pharmaceutical products but without the harmful side effects. You can find more information about this trial and our other published studies at https://arcadetherapeutics.com/research/

Arcade's Co-Founders bring together world-class scientific knowledge with experience building consumer products across healthcare, media and tech-enabled services. We've added amazing advisors to the team that bring game strategy, regulatory, and commercial expertise to support our goals.

GO TO MARKET. Our go to market strategy is B2B2C, allowing partners to make our treatments available to their patients or clients. We have contracted with a number of partners for pilot programs in primary care, tele-health, universities, and behavioral health.

Our pricing model for StarStarter is based on $75 / 90 day Treatment, with discounts available in volume. In the future, we expect that insurance based reimbursement will allow our products to scale to even larger populations as a first line treatment.

• Our referral based programs allow patients to receive discounted access from their provider.
• Enterprise model allows a partner to pay for their organization to have access.
• Through our integrated ArcadeConnect platform, we can also support reporting and billing requirements allowing long term reimbursement from insurance.

Sources: NIMH, Best Colleges, NEA, Commonwealth

Our products come with an integrated clinical platform for secure registration, periodic assessments, and data management to support personalization and triage. In this way we can integrate with existing services to engage with patients earlier, and provide escalation paths that help them take appropriate next steps.

FUTURE PRODUCTS. We were also co-awarded a $3.8M grant from the NIMH with UT Austin to fund a clinical trial for a treatment for Major Depressive Disorder. This new product has already been piloted, and has shown promising results as our next major therapeutic area.

GO TO MARKET. Our projected revenue is based on deployments across our priority segments, using scaling pricing starting at $75 per treatment for non-prescription anxiety to approximately $300 for depression treatment, supported by newly released Digital Mental Health Treatment codes. We also intend to license these products into international markets. The additional opportunity of combination products to improve effectiveness of pharmaceutical products is not fully captured yet as this is a new and rapidly evolving opportunity.

Future projections are not guaranteed.

USE OF PROCEEDS. Our Equity Crowdfunding Round will support early rollouts of our therapeutic games through trusted organizations, along with support for FDA Clearances that support our long term goals of making effective treatments available in scale. 

Funds will be used to execute on revenue and product deployment milestones to achieve early revenue scale of $1.5MM-$2MM ARR prior to Series A

• Non-prescription Anxiety launches. Primary Care, Universities, BH and Tele-Therapy segments
• Core Operations and Client Support. Support for client operations and sales to achieve penetration targets. Maintenance of technology and game development.
• FDA Submission Process for Depression. Clinical trial and FDA submission support for of ABM-02 (Depression) being managed by UT Austin with $3.8M NIMH Grant. 
• Licensing and Co-Development for Expanded Opportunities. Support for pharma combination opportunities, international licensing and co-development leveraging our IP and game development capabilities.

Current Investors:

Thank you for learning about our Equity Crowdfunding Offering. We welcome you to join our mission to change the game in mental health!